Genetic and chemotherapeutic influences on germline hypermutation.
Genomics England Research Consortium
Springer Science and Business Media LLC
MetadataShow full item record
Kaplanis, J., Ide, B., Sanghvi, R., Neville, M., Danecek, P., Coorens, T., Prigmore, E., et al. (2022). Genetic and chemotherapeutic influences on germline hypermutation.. Nature, 605 (7910), 503-508. https://doi.org/10.1038/s41586-022-04712-2
Funder: British Heart Foundation
Mutations in the germline generates all evolutionary genetic variation and is a cause of genetic disease. Parental age is the primary determinant of the number of new germline mutations in an individual's genome1,2. Here we analysed the genome-wide sequences of 21,879 families with rare genetic diseases and identified 12 individuals with a hypermutated genome with between two and seven times more de novo single-nucleotide variants than expected. In most families (9 out of 12), the excess mutations came from the father. Two families had genetic drivers of germline hypermutation, with fathers carrying damaging genetic variation in DNA-repair genes. For five of the families, paternal exposure to chemotherapeutic agents before conception was probably a key driver of hypermutation. Our results suggest that the germline is well protected from mutagenic effects, hypermutation is rare, the number of excess mutations is relatively modest and most individuals with a hypermutated genome will not have a genetic disease.
Age Factors, Genetic Diseases, Inborn, Germ Cells, Germ-Line Mutation, Humans, Male, Mutagenesis, Mutation, Parents, Polymorphism, Single Nucleotide
Wellcome Trust (206194)
External DOI: https://doi.org/10.1038/s41586-022-04712-2
This record's URL: https://www.repository.cam.ac.uk/handle/1810/338023
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com